You are here

Yescarta

Kite publishes Phase II data for Yescarta in treating B-cell lymphoma

Kite publishes Phase II data for Yescarta in treating B-cell lymphoma

Clinical Trials Arena

Gilead Sciences

clinical trials

relapsed or refractory large B-cell lymphoma

Flag link:

Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma

Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma

Businesswire

Gilead Sciences

relapsed or refractory large B-cell lymphoma

Flag link:

Gilead’s Yescarta extends survival in lymphoma study

Gilead’s Yescarta extends survival in lymphoma study

BioPharma Dive

Gilead Sciences

large B-cell lymphoma

Flag link:

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

Fierce Pharma

Gilead Sciences

Flag link:

Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences

Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences

NASDAQ.com

Gilead Sciences

Flag link:

Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers

Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers

Fierce Pharma

Gilead Sciences

Bristol Myers Squibb

Flag link:

Gilead's Yescarta eyes first to move up lymphoma ladder in Europe amid busy week at EMA

Gilead's Yescarta eyes first to move up lymphoma ladder in Europe amid busy week at EMA

Fierce Pharma

Gilead Sciences

diffuse large B-cell lymphoma

high-grade B-cell lymphoma

Flag link:

Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead

Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead

Biopharma Reporter

Gilead Sciences

drug manufacturing

Flag link:

Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030

Gilead, after setbacks, aims to pull a third of its revenue from oncology business by 2030

Fierce Pharma

Gilead Sciences

Flag link:

Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst

Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst

Fierce Pharma

Gilead Sciences

Flag link:

ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma

ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma

Fierce Pharma

Gilead Sciences

Bristol Myers Squibb

Flag link:

What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More

What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More

OBR Oncology

Flag link:

New fault lines emerge in CAR-T therapy

New fault lines emerge in CAR-T therapy

EP Vantage

Bristol Myers Squibb

Gilead Sciences

clinical trials

Flag link:

Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients

Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients

Endpoints

Gilead Sciences

relapsed or refractory diffuse large B-cell lymphoma

Flag link:

#ASCO21: Novartis gears up for CAR-T fight with Gilead in follicular lymphoma — and safety could define the battle

#ASCO21: Novartis gears up for CAR-T fight with Gilead in follicular lymphoma — and safety could define the battle

Endpoints

follicular lymphoma

Gilead Sciences

Flag link:

Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting

Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting

Biopharma Reporter

Flag link:

ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy

ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy

Fierce Pharma

Gilead Sciences

diffuse large B-cell lymphoma

clinical trials

Flag link:

Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas

Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas

MedCity News

Gilead Sciences

follicular lymphoma

marginal zone lymphoma

Flag link:

Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online

Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online

Fierce Pharma

Gilead Sciences

drug manufacturing

Flag link:

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

Fierce Pharma

Gilead Sciences

refractory large B-cell lymphoma

Flag link:

Pages